In today’s briefing:
- 4 Spin-offs with Insider Buying
- Analog Devices Pushing For Increased Industrial Automation With An Interesting Power-Saving Tech – What Does This Mean For Investors?
- Lululemon 4Q’24 Update
- CoreWeave Inc (CRWV): IPO Opens Below Issue, Closes Flat in Debut Session
- [ETP 2025/13] WTI Climbs on Trade Disruptions, Moderate Weather Forecasts Cap Henry Hub
- MoneyHero: Three Key Questions Critical to the Investment Thesis
- IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer
- Freshpet’s Recent Market Growth & Household Penetration Expansion
- Leggett & Platt: Focus On Expanding High-End Bedding Market To Enable Margin Expansion!
- SentinelOne Skyrockets with Enterprise Client Surge & Soaring Deal Sizes!
4 Spin-offs with Insider Buying
- One factor that I closely follow in the spin-off universe is insider buying.
- Here’s what Peter Lynch wrote about insiders and spin-offs in One Up on Wall Street: [Spin-offs] are a fertile area for amateur investors…….A month or two after the spinoff is completed, you can check to see if there is heavy insider buying among the new officers and directors.
- There are four names in my universe that have interesting insider activity.
Analog Devices Pushing For Increased Industrial Automation With An Interesting Power-Saving Tech – What Does This Mean For Investors?
- Analog Devices, Inc. (ADI) reported its financial results for the first quarter of fiscal year 2025, showing better than-anticipated performance despite prevailing macroeconomic and geopolitical challenges.
- Revenue reached $2.42 billion, surpassing the midpoint of its outlook, although this marked a 4% year-over-year decline.
- When adjusted for an extra week in the comparable period last year, sales represented a 4% year-over-year increase.
Lululemon 4Q’24 Update
- Since its IPO back in 2007, Lululemon always posted double-digit revenue growth every single year.
- While there was plenty of skepticism throughout 2024, they managed to eke out double digit growth last year.
- But 2025 topline guidance of 5-7% implies the era of persistent double digit growth regardless of the economy is likely behind us!
CoreWeave Inc (CRWV): IPO Opens Below Issue, Closes Flat in Debut Session
- CoreWeave priced a down-sized transaction of 37.5mm shares at $40.00 ($7 Below the Original $47-$55 range) and opened at $39.00 for a loss of 2.5% at first trade
- According to our underwriter sources, the deal finished multiple-times oversubscribed with the top three accounts getting 50% of the deal and the top 15 accounts taking down 90% of the transaction.
- This IPO in particular was a difficult deal to value for IPO investors based upon being a “first mover” in the AI space.
[ETP 2025/13] WTI Climbs on Trade Disruptions, Moderate Weather Forecasts Cap Henry Hub
- For the week ending 21/Mar, U.S. crude inventories fell by 3.3m barrels (vs. expectations of 1.5m build), gasoline and distillate stockpiles fell less than expected.
- US natural gas inventories rose by 37 Bcf for the week ending 21/Mar, in line with analyst expectations. Inventories are 6.5% below the 5-year seasonal average.
- Shell to boost shareholder distributions to 40-50% of CFFO and cut costs by USD 5-7 billion by 2028. Exxon plans 250 layoffs in the UK by 2026.
MoneyHero: Three Key Questions Critical to the Investment Thesis
- We believe addressing these three key areas remains essential for strengthening the investment thesis and enhancing investors’ confidence in the company’s long-term value proposition.
- 1) The company’s differentiation strategy within the relatively crowded Hong Kong and Singapore insurance marketplaces; 2) its insurance offerings’ product market fit; 3) disclosure on cross-selling metrics going forward
- We think articulating a comprehensive strategy and detailed implementation roadmap, targeting these key areas, can enhance investor confidence and potentially provide support for the company’s valuation.
IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer
- On March 25, 2025, Imunon, Inc. (IMNN) held a conference call to discuss the finalized protocol for a Phase 3 clinical trial of IMNN-001 in patients with newly diagnosed ovarian cancer.
- The study will mirror the Phase 2 OVATION 2 trial that reported benefits in both progression-free and overall survival.
- It will initially focus on those patients who are positive for homologous recombination deficiency (HDR) positive, including BRCA1 and BRCA2 mutations.
Freshpet’s Recent Market Growth & Household Penetration Expansion
- Freshpet delivered a strong performance in the fiscal year 2024, characterized by notable growth in net sales and even more significant improvements in profitability.
- The company’s net sales reached $975 million, marking a 27% increase from the previous year, driven largely by volume gains.
- This was predominantly a result of increased household penetration and buy rates, boosted by strategic media investments and retail expansion.
Leggett & Platt: Focus On Expanding High-End Bedding Market To Enable Margin Expansion!
- Leggett & Platt’s fourth-quarter and full-year 2024 results reflect a challenging market environment with mixed outcomes from restructuring efforts and demand dynamics across its segments.
- Throughout 2024, Leggett & Platt undertook significant restructuring, particularly in its Bedding Products segment, as well as in home furniture, flooring products, and hydraulic cylinders.
- The company exceeded its target for restructuring EBIT benefits, achieving $22 million, which was above the expected $10 million to $15 million, indicating successful execution of the restructuring plans.
SentinelOne Skyrockets with Enterprise Client Surge & Soaring Deal Sizes!
- SentinelOne reported strong financial results for the fourth quarter and fiscal year 2025, with significant achievements and certain challenges that are crucial for investors to assess.
- The company experienced noteworthy revenue growth, reaching $226 million in Q4, marking a 29% increase year-over-year.
- The total revenue for fiscal year 2025 amounted to $821 million, demonstrating an annual growth rate of 32%.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
